Submissions from 2018

Lenalidomide maintenance therapy after autologous peripheral blood stem cell transplant (pbsct) in multiple myeloma patients: Factors that impact treatment., Pushpinderdeep Kahlon, N K. Sandhu, Philip Kuriakose, and Edward Peres

Horsies and bunnies: A comparison of antithymocyte globulin in allogeneic stem cell transplant., C Lu, Klodiana Neme, Nancy Mikulandric, Meredith Grycki, D Pelland, Shatha Farhan, Nalini Janakiraman, Edward Peres, V Vogel, and E Szandzik

Primary versus secondary autoimmune hemolytic anemia: A retrospective analysis of diagnostic patterns and treatment outcomes, Laurel Mueller, Hussna Abunafessa, Diego Cabrera-Fernandez, and Philip Kuriakose

Busulfan pharmacokinetics and cd4 reconstitution after stem cell transplant in patients with myeloid neoplasms., Neha Patil, Michael Bazydlo, Edward Peres, Nalini Janakiraman, and Shatha Farhan

Dynamic pro-survival signaling mediates resistance to androgen receptor targeted therapy in ARv7 splice variant expressing prostate cancer models., Amanda B. Pilling and Clara Hwang

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study, Suman L. Sood, Dunlei Cheng, Amy Shapiro, Craig M. Kessler, Nigel S. Key, Doris Quon, M. Elaine Eyster, Marilyn J. Manco-Johnson, Christine L. Kempton, Adam Cuker, Margaret V. Ragni, Philip Kuriakose, Annette von Drygalski, Peter A. Kouides, Miguel A. Escobar, Allison P. Wheeler, Tzu-Fei Weng, Cindy A. Leissinger, Sarah Galdzicka, and Barbara A. Konkle

A case of thrombotic thrombocytopenic purpura and pancreatitis as a result of milk-alkali syndrome., B Souther, A Patel, and L Sutkowi-Toomajian

A case of thrombotic thrombocytopenic purpura and pancreatitis as a result of milk-alkali syndrome, B. Souther, A. Patel, and Lynette Sutkowi-Toomajian

Institutional adherence to National Comprehensive Cancer Network (NCCN) guidelines in neoadjuvant treatment of breast cancer and its correlation to outcomes., R K. Vaddepally, A Hejab, and Haythem Y. Ali

Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial., U N. Vaishampayan, L K. Heilbrun, P Monk, Sheela Tejwani, G Sonpavde, D Smith, P Jasti, K Dobson, E I. Heath, M L. Cher, S Chinni, and J A. Fontana

Enhancing psychosocial screening, surveillance, and management of Oncology Care Model patients under treatment with palliative intent, T Varkas, Michael Ryan, D Harrison, Daniel J. Miller, A Williams, and W Goldberg

Socioeconomic differences in distress among patients with cancer., Amy M. Williams, Michael Ryan, T Varkas, and W Goldberg

Antiplatelet Therapy for Patients with Hemophilia after Percutaneous Coronary Intervention, Peter Xie, Devin Malik, and Philip Kuriakose

Implementation of oral chemotherapy management program in the large integrated health care system and its impact on patient safety, J Yoo, S Nhean, P Vogel, I Rybkin, and Diana Kostoff

Submissions from 2017

Poor concordance between 21-gene expression assay recurrence score and all Magee equation recurrence scores in a consecutive cohort of patients treated for hormone receptor positive early breast cancer., Z Abdel-Rahman, Haythem Y. Ali, Laura Favazza, and Dhananjay A. Chitale

A mysterious cause of chest pain., Z Abdel-Rahman, Yaser Alkhatib, and Vrushali Dabak

Hematology referrals for mild thrombocytopenia in a tertiary center in detroit: A step towards a standardized approach for referrals and testing., Z Abdel-Rahman, K Alsafadi, H Jabbour, Vivek Mendiratta, Yaser Alkhatib, and Vijayalakshmi Donthireddy

Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients., A B. Apolo, J Ellerton, J R. Infante, M Agrawal, M S. Gordon, R Aljumaily, C D. Britten, L Dirix, K W. Lee, M H. Taylor, P Schoffski, Ding Wang, A Ravaud, A Gelb, J Xiong, G Rosen, and M R. Patel

A Phase 1-2 dose-escalation and cohort- expansion study of eFT508, a selective, orally bioavailable inhibitor of MNK1 and MNK2, in patients with hematological malignancies., A K. Gopal, R Ramchandren, N Y. Gabrail, M R. Patel, Ding Wang, L L. Miller, V Goel, G G. Chiang, K R. Webster, S Sperry, D T. Vallner, C Casseday, and J Barton

Clinical and nonclinical factors associated with confirmatory biopsy in metastatic breast cancer., J J. Griggs, T Braun, Dawn Severson, E M. Layhe, D H. Gorski, T M. Breslin, and N L. Henry

Site variation in assessment of biomarkers on biopsy specimens in patients with metastatic disease., J J. Griggs, T Braun, Dawn Severson, E M. Layhe, D H. Gorski, T M. Breslin, and N L. Henry

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01., A Gucalp, M A. Danso, A D. Elias, A Bardia, Haythem Y. Ali, D Potter, N Y. Gabrail, B B. Haley, H T. Khong, E C. Riley, L Ervin, J R. Eisner, E Baskin-Bey, W R. Moore, and T A. Traina

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456., W A. Harb, M J. Edelman, S K. Chambers, L L. Garland, A Armour, Ding Wang, G D. Goss, and J Sachdev

A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin., W A. Harb, L S. Rosen, Ding Wang, M Fakih, D Mahadevan, W Clemens, G Selvaggi, S Bosque, R Brown, S Alvis, B Champion, and H McElwaine-Johnn

Timing of percutaneous endoscopic gastrostomy (PEG) tube placement as supportive care in HNSCC patients (Pts) receiving concurrent chemoradiotherapy (CRT)., Oleksandra Lupak, Michael Bazydlo, F Siddiqui, Steven S. Chang, Bryan Coniglio, and Ding Wang

Evaluating the clinical utility of testing for autoimmune disorders in the setting of leukopenia/neutropenia in an ambulatory hematology clinic., Devin Malik, Philip Kuriakose, Joyce Philip, Amal Hejab, Alexander Horbal, and Vivek Mendiratta

Phase 2 study of glesatinib or sitravatinib with nivolumab in non-small cell lung cancer (NSCLC) after checkpoint inhibitor therapy., J Nemunaitis, H Borghaei, W Akerley, S Gadgeel, A Spira, I Rybkin, D Faltaos, I Chen, J Christensen, D Potvin, K Velastegui, M Levisetti, and H Husain

Effect of follow-up appointments and admission unit on readmissions in patient with cancer on chemotherapy: A tertiary center experience., Z A. Rahman, J Philip, Omar Mohtadi, Pushpinderdeep Kahlon, and Vijayalakshmi Donthireddy

Comparison of high dose methotrexate treatments in CNS lymphoma patients: The Henry Ford experience., Ranya Selim, J Philip, and Vijayalakshmi Donthireddy

Chronic kidney disease in the U.S. Hemophilia population: A cohort study., S L. Sood, D Cheng, A D. Shapiro, C M. Kessler, N S. Key, Doris V. Quon, M E. Eyster, Marilyn J. Manco-Johnson, Christine L. Kempton, Adam Cuker, M V. Ragni, J C. Gill, Philip Kuriakose, A Von Drygalski, P Kouides, M A. Escobar, A P. Wheeler, T Wang, C A. Leissinger, S Galdzicka, and B Konkle

Venetoclax (VEN), bendamustine (B) and rituximab (R) in patients (PTs) with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Final results of a phase I study., L J. Swinnen, C R. Flowers, Ding Wang, E Reid, N Fowler, J Cordero, M Dunbar, S Enschede, C Nolan, A M. Petrich, J Ross, A H. Salem, M Verdugo, S Wong, L Zhou, M Kozloff, L Nastoupil, and S DeVos

Nonspecific tumor markers in the era of value based medicine: Role of CA 19-9 in the pelvic mass workup, J Underwood, Haleema Saeed, E Y. Chae, and Rabbie K. Hanna

A Study of MGCD516, a receptor tyrosine kinase (RTK) inhibitor, in molecularly selected patients with NSCLC or other advanced solid tumors., T Werner, R Heist, R Carvajal, D Adkins, A Alva, S Goel, D Hong, L Bazhenova, M Saleh, R Siegel, C Kyriakopoulos, C Blakely, K Eaton, R Lauer, Ding Wang, G Schwartz, S Neuteboom, D Potvin, D Faltaos, I Chen, J Christensen, M Levisetti, R Chao, and T Bauer

Distress screening for program building: Similarities and differences among patient populations., Amy M. Williams, W Goldberg, T Varkas, and Michael Ryan

nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial., D Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, Haythem Y. Ali, J Eakel, A Schneeweiss, L D. Merino, S Wilks, J O'Shaugnessy, S Gluck, H Li, R Beck, D Barton, and N Harbeck